Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine

15-10-2024 | Heart Failure | CE-REVIEW

Deprescribing strategies in older patients with heart failure

Authors: Gregorio Tersalvi, Vittorio Beltrani, Marco Peronti, Ludovico Furlan, Andrew Foy, Luigi Biasco

Published in: Internal and Emergency Medicine

Login to get access

Abstract

Older patients with heart failure are particularly vulnerable due to a wide range of associated comorbidities, disability, and frailty. This population often receives multiple prescriptions, increasing the risk of adverse drug reactions, non-adherence, and drug interactions. Deprescribing, which involves reducing the number of medications to the lowest clinically reasonable limit, has the potential to decrease the risk of drug interactions and enhance patients’ quality of life. Moreover, simplifying medication regimens may improve adherence to essential heart failure therapies. This scientific review aims to comprehensively examine deprescribing strategies in older patients with heart failure. It explores the rationale, challenges, benefits, and potential approaches to optimizing medication regimens in this vulnerable population. Furthermore, the review suggests a practical, step-by-step approach for performing deprescribing in older patients with heart failure.
Literature
1.
2.
Tersalvi G, Gasperetti A, Schiavone M et al (2021) Acute heart failure in elderly patients: a review of invasive and non-invasive management. J Geriatr Cardiol 18:560–576PubMedPubMedCentral
3.
4.
5.
Gnjidic D, Hilmer SN, Blyth FM et al (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65:989–995PubMedCrossRef
6.
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18:891–975PubMedCrossRef
7.
8.
Sukumar S, Orkaby AR, Schwartz JB et al (2022) Polypharmacy in older heart failure patients: a multidisciplinary approach. Curr Heart Fail Rep 19:290–302PubMedCrossRef
9.
10.
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-156PubMedCrossRef
11.
Vitale C, Jankowska E, Hill L et al (2019) Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 21:1299–1305PubMedCrossRef
12.
Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227–3337PubMedCrossRef
13.
Khan H, Kalogeropoulos AP, Georgiopoulou VV et al (2013) Frailty and risk for heart failure in older adults: the health, aging, and body composition study. Am Heart J 166:887–894PubMedCrossRef
14.
Denfeld QE, Winters-Stone K, Mudd JO et al (2017) The prevalence of frailty in heart failure: a systematic review and meta-analysis. Int J Cardiol 236:283–289PubMedPubMedCentralCrossRef
15.
Bielecka-Dabrowa A, Ebner N, Santos MR et al (2020) Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail 22:ejhf.2011CrossRef
16.
Hamada T, Kubo T, Kawai K et al (2023) Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail 10:223–233PubMedCrossRef
17.
Lee Y-C, Lin JK, Ko D et al (2023) Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction. J Am Geriatr Soc 71:3110–3121PubMedPubMedCentralCrossRef
18.
Dewan P, Jackson A, Jhund PS et al (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction—an analysis of PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail 22:2123–2133PubMedCrossRef
19.
Yang X, Lupón J, Vidán MT et al (2018) Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta-analysis. J Am Heart Assoc 7:e008251PubMedPubMedCentralCrossRef
20.
Ohashi K, Matsue Y, Maeda D et al (2024) Impact of multidomain frailty on the mode of death in older patients with heart failure: a cohort study. Circ Cardiovasc Qual Outcomes 17(5):e010416PubMed
21.
22.
Beezer J, Al Hatrushi M, Husband A et al (2022) Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev 27:465–492PubMedCrossRef
23.
McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef
24.
McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 28:ehad195
25.
Khan MS, Samman Tahhan A, Vaduganathan M et al (2020) Trends in prevalence of comorbidities in heart failure clinical trials: comorbidities in HF clinical trials. Eur J Heart Fail 22:1032–1042PubMedCrossRef
26.
Tersalvi G, Bossard M, Aeschbacher S et al (2024) Prevalence and outcomes of heart failure phenotypes in patients with atrial fibrillation. Int J Cardiol 412:132320PubMedCrossRef
27.
Verdiani V, Panigada G, Fortini A et al (2015) The heart failure in Internal Medicine in Tuscany: the SMIT Study. Ital J Med 9:349CrossRef
28.
Khan MS, Singh S, Segar MW et al (2023) Polypharmacy and optimization of guideline-directed medical therapy in heart failure. JACC Heart Fail 11:S2213177923001373CrossRef
29.
Cobretti MR, Page RL, Linnebur SA et al (2017) Medication regimen complexity in ambulatory older adults with heart failure. Clin Interv Aging 12:679–686PubMedPubMedCentralCrossRef
30.
Wimmer BC, Bell JS, Fastbom J et al (2016) Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study. Ann Pharmacother 50:89–95PubMedPubMedCentralCrossRef
31.
Veehof L, Stewart R, Haaijer-Ruskamp F et al (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267PubMedCrossRef
32.
Gnjidic D, Le Couteur DG, Pearson S-A et al (2013) High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health 13:115PubMedPubMedCentralCrossRef
33.
Halli-Tierney AD, Scarbrough C, Carroll D (2019) Polypharmacy: evaluating risks and deprescribing. Am Fam Physician 100(1):32–38PubMed
34.
Cussans A, Harvey G, Kemple T et al (2021) Interventions to reduce the environmental impact of medicines: a UK perspective✰. J Clim Change Health 4:100079CrossRef
35.
Foy AJ, Brown DL (2023) Importance of designing trials for older adults with complex medical conditions. JAMA Intern Med 183:415PubMedCrossRef
36.
37.
Shah SJ, Van Walraven C, Jeon SY et al (2024) Estimating vitamin K antagonist anticoagulation benefit in people with atrial fibrillation accounting for competing risks: evidence from 12 randomized trials. Circ Cardiovasc Qual Outcomes 17:e010269PubMedCrossRef
38.
Warner V, Nguyen D, Bayles T et al (2022) Management of heart failure in older people. Pharm Pract Res 52:72–79CrossRef
39.
Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938–1952PubMedCrossRef
40.
Arrigo M, Biegus J, Asakage A et al (2023) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail 25:1145–1155PubMedCrossRef
41.
Barry AR, Grewal M, Blain L (2023) Use of guideline-directed medical therapy in patients aged 80 years or older with heart failure with reduced ejection fraction. CJC Open 5:303–309PubMedPubMedCentralCrossRef
42.
Stolfo D, Lund LH, Becher PM et al (2022) Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 24:1047–1062PubMedCrossRef
43.
Veenis JF, Brunner-La Rocca H-P, Linssen GC et al (2019) Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol 26:1399–1407PubMedPubMedCentralCrossRef
44.
Seo W-W, Park JJ, Park HA et al (2020) Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open 10:e030514PubMedPubMedCentralCrossRef
45.
Goyal P, Zullo AR, Gladders B et al (2023) Real-world safety of neurohormonal antagonist initiation among older adults following a heart failure hospitalization. ESC Heart Fail 10:1623–1634PubMedPubMedCentralCrossRef
46.
Rothwell PM (2005) Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365:176–186PubMedCrossRef
47.
Flather MD, Shibata MC, Coats AJS et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225PubMedCrossRef
48.
Kotecha D, Holmes J, Krum H et al (2014) Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:2235–2243PubMedCrossRef
49.
Molnar AO, Petrcich W, Weir MA et al (2020) The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrol Dial Transpl 35:782–789CrossRef
50.
Kotecha D, Gill SK, Flather MD et al (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol 74:2893–2904PubMedCrossRef
51.
Palau P, Seller J, Domínguez E et al (2021) Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78:2042–2056PubMedCrossRef
52.
Flather MD, Yusuf S, Køber L et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355:1575–1581PubMedCrossRef
53.
Dickstein K, Kjekshus J (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360:752–760PubMedCrossRef
54.
Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRef
55.
Heran BS, Musini VM, Bassett K et al (2012) Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012:CD003040PubMedPubMedCentral
56.
Jhund PS, Fu M, Bayram E et al (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 36:2576–2584PubMedPubMedCentralCrossRef
57.
Gatti M, Antonazzo IC, Diemberger I et al (2021) Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol 28:983–989PubMedCrossRef
58.
Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef
59.
Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedCrossRef
60.
Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med:NEJMoa2407107
61.
Ferreira JP, Rossello X, Eschalier R et al (2019) MRAs in elderly HF patients. JACC Heart Fail 7:1012–1021PubMedCrossRef
62.
Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455–462PubMedCrossRef
63.
Beldhuis IE, Myhre PL, Claggett B et al (2019) Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail 7:25–32PubMedCrossRef
64.
Savarese G, Carrero J, Pitt B et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20:1326–1334PubMedCrossRef
65.
Jonsson Holmdahl A, Wessberg G, Norberg H et al (2022) Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. Open Heart 9:e002022PubMedPubMedCentralCrossRef
66.
Larsson JE, Denholt CS, Thune JJ et al (2023) Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 9:546–552PubMedCrossRef
67.
Martinez FA, Serenelli M, Nicolau JC et al (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 141:100–111PubMedCrossRef
68.
Filippatos G, Anker SD, Butler J et al (2022) Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced. Eur J Heart Fail 24:2297–2304PubMedCrossRef
69.
Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098PubMedCrossRef
70.
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMedCrossRef
71.
Liu Y, An C, Liu P et al (2023) Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. Ren Fail 45:2217287PubMedPubMedCentralCrossRef
72.
73.
Böhm M, Butler J, Filippatos G et al (2022) Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age. J Am Coll Cardiol 80:1–18PubMedCrossRef
74.
Butt JH, Jhund PS, Belohlávek J et al (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation 146:1210–1224PubMedPubMedCentralCrossRef
75.
Butt JH, Dewan P, Merkely B et al (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial. Ann Intern Med 175:820–830PubMedCrossRef
76.
Hias J, Hellemans L, Walgraeve K et al (2022) SGLT2 inhibitors in older adults with heart failure with preserved ejection fraction. Drugs Aging 39:185–190PubMedCrossRef
77.
Seferović PM, Fragasso G, Petrie M et al (2020) Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22:1495–1503PubMedCrossRef
78.
Qiu M, Ding L-L, Zhang M et al (2021) Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res 18:14791641211011016PubMedPubMedCentralCrossRef
79.
Pollack R, Cahn A (2022) SGLT2 inhibitors and safety in older patients. Heart Fail Clin 18:635–643PubMedCrossRef
80.
Jansen S, Bhangu J, De Rooij S et al (2016) The association of cardiovascular disorders and falls: a systematic review. J Am Med Dir Assoc 17:193–199PubMedCrossRef
81.
Goyal P, Anderson TS, Bernacki GM et al (2020) Physician perspectives on deprescribing cardiovascular medications for older adults. J Am Geriatr Soc 68:78–86PubMedCrossRef
82.
Montero-Odasso M, Van Der Velde N, Martin FC et al (2022) World guidelines for falls prevention and management for older adults: a global initiative. Age Age 51:afac205CrossRef
83.
Scott IA, Hilmer SN, Reeve E et al (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175:827–834PubMedCrossRef
84.
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel (2023) American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 71:2052–2081CrossRef
85.
O’Mahony D, Gallagher P, Ryan C et al (2010) STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med 1:45–51CrossRef
86.
Zhou D, Chen Z, Tian F (2023) Deprescribing interventions for older patients: a systematic review and meta-analysis. J Am Med Direct Assoc 24:S152586102300645XCrossRef
87.
Martin P, Tamblyn R, Benedetti A et al (2018) Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA 320:1889PubMedPubMedCentralCrossRef
88.
Vasilevskis EE, Shah AS, Hollingsworth EK et al (2023) Deprescribing medications among older adults from end of hospitalization through postacute care: a shed-meds randomized clinical trial. JAMA Intern Med 183:223PubMedPubMedCentralCrossRef
89.
Herrinton LJ, Lo K, Alavi M et al (2023) Effectiveness of bundled hyperpolypharmacy deprescribing compared with usual care among older adults: a randomized clinical trial. JAMA Netw Open 6:e2322505PubMedPubMedCentralCrossRef
90.
McDonald EG, Wu PE, Rashidi B et al (2022) The MedSafer study—electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med 182:265PubMedCrossRef
91.
Ibrahim K, Cox NJ, Stevenson JM et al (2021) A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr 21:258PubMedPubMedCentralCrossRef
92.
Navid P, Nguyen L, Jaber D et al (2021) Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction. J Am Geriatr Soc 69:1948–1955PubMedPubMedCentralCrossRef
93.
Beezer J, Roe L, Husband A (2022) A retrospective cohort review of prescribing in hospitalised patients with heart failure using Beers criteria and STOPP recommendations. Pharm Pract Res 52:132–138CrossRef
94.
Punnoose LR, Givertz MM, Lewis EF et al (2011) Heart failure with recovered ejection fraction: a distinct clinical entity. J Cardiac Fail 17:527–532CrossRef
95.
Hopper I, Samuel R, Hayward C et al (2014) Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis. J Cardiac Fail 20:522–532CrossRef
96.
Rossello X, Pocock SJ, Julian DG (2015) Long-term use of cardiovascular drugs. J Am Coll Cardiol 66:1273–1285PubMedCrossRef
97.
Bursi F, Weston SA, Redfield MM et al (2006) Systolic and diastolic heart failure in the community. JAMA 296:2209–2216PubMedCrossRef
98.
Redfield MM, Borlaug BA (2023) Heart failure with preserved ejection fraction: a review. JAMA 329:827PubMedCrossRef
99.
McDonagh TA, Blue L, Clark AL et al (2011) European society of cardiology heart failure association standards for delivering heart failure care. Eur J Heart Fail 13:235–241PubMedCrossRef
100.
Adler ED, Goldfinger JZ, Kalman J et al (2009) Palliative care in the treatment of advanced heart failure. Circulation 120:2597–2606PubMedCrossRef
101.
Schuling J, Gebben H, Veehof LJG et al (2012) Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 13:56PubMedPubMedCentralCrossRef
102.
Milfred-LaForest SK, Chow SL, DiDomenico RJ et al (2013) Clinical pharmacy services in heart failure: an opinion paper from the heart failure society of America and American College of Clinical Pharmacy Cardiology practice and research network. J Cardiac Fail 19:354–369CrossRef
103.
104.
Kutner JS, Blatchford PJ, Taylor DH et al (2015) Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 175:691PubMedPubMedCentralCrossRef
105.
Van Poelgeest EP, Handoko ML, Muller M et al (2023) Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review. Eur Geriatr Med 14:659–674PubMedPubMedCentralCrossRef
106.
Martens P, Verbrugge FH, Boonen L et al (2018) Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol 250:171–175PubMedCrossRef
107.
Damman K, Masson S, Lucci D et al (2017) Progression of renal impairment and chronic kidney disease in chronic heart failure: an analysis from GISSI-HF. J Card Fail 23:2–9PubMedCrossRef
108.
Metadata
Title
Deprescribing strategies in older patients with heart failure
Authors
Gregorio Tersalvi
Vittorio Beltrani
Marco Peronti
Ludovico Furlan
Andrew Foy
Luigi Biasco
Publication date
15-10-2024

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits